STB

IBCAP credits industry-leading automation tools for its 2022 success in removing pirated content worldwide

Retrieved on: 
Thursday, January 26, 2023

DENVER, Jan. 26, 2023 (GLOBE NEWSWIRE) -- The International Broadcaster Coalition Against Piracy (IBCAP) today announced key 2022 achievements in protecting its members’ content and removing pirate services from the U.S. market and worldwide.

Key Points: 
  • DENVER, Jan. 26, 2023 (GLOBE NEWSWIRE) -- The International Broadcaster Coalition Against Piracy (IBCAP) today announced key 2022 achievements in protecting its members’ content and removing pirate services from the U.S. market and worldwide.
  • Additional 2022 highlights include:
    IBCAP-coordinated lawsuits securing wide-reaching legal injunctions and judgments totaling more than $50 million.
  • In addition, IBCAP’s enforcement of injunctions and other persistent takedown efforts in 2022 often resulted in the removal of pirated content worldwide, not just in the U.S. market.
  • This collateral benefit makes membership in IBCAP even more valuable for content owners with a global presence.

Syntekabio Inc.: 2023 Trends in New Drug Development

Retrieved on: 
Thursday, February 2, 2023

The webinar features panelists from Columbia University, Janssen, Syntekabio (KOSDAQ:226330.KQ) and Auctus Capital

Key Points: 
  • The webinar features panelists from Columbia University, Janssen, Syntekabio (KOSDAQ:226330.KQ) and Auctus Capital
    Syntekabio (KOSDAQ:226330.KQ)(226330:KS), a global AI drug discovery and development company, will participate in a special webinar hosted by the New York Health Forum (NYHF) on the latest drug discovery and development trends.
  • What is at the core of transforming a once lengthy process full of complexity and uncertainties?
  • Advancements in new technologies, including artificial intelligence (AI), Covid-19 and drug pricing legislation have disrupted drug discovery and development in the global biopharma industry.
  • Syntekabio is leading this industry-wide transformation with its latest invention STB CLOUD, which can give clinical-stage pharmaceutical companies with limited drug discovery capability an ideal one-stop solution for fully automatic drug discovery.

New Cloud Platform “STB CLOUD” Disrupts AI Drug Discovery Worldwide

Retrieved on: 
Sunday, January 22, 2023

Powered by Syntekabio’s own MAHA supercomputing, the AI-based one-stop cloud service system STB CLOUD ensures the efficient discovery of small molecule drug candidates

Key Points: 
  • Powered by Syntekabio’s own MAHA supercomputing, the AI-based one-stop cloud service system STB CLOUD ensures the efficient discovery of small molecule drug candidates
    Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, has launched STB CLOUD worldwide.
  • Running on Syntekabio’s own supercomputing infrastructure, the new AI drug discovery cloud platform is driven by genomic big data and the latest AI technology.
  • By integrating DeepMatcher®, an AI-driven small molecule drug discovery platform, this new service has automated AI computing function within its own supercomputing hardware environment and database into the cloud system.
  • Improving standardization, simplification and automation of the existing computer-aided drug discovery (CADD) process optimizes the drug discovery and development process far better in terms of time, cost, accuracy and resources.

 Sercomm Showcases Next-Gen IP Streamers, AI-Powered Smart Home Devices, Small Cell Solutions, and More at CES 2023

Retrieved on: 
Thursday, December 22, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221221005646/en/
    Sercomm's Next-Gen IP streamers, AI-powered smart home devices, small cell solutions, and more being showcased at CES 2023.
  • Product demonstrations and solutions on display include:
    Next-Gen IP Streamers & STBs, including RDK and Android-based software capable of 4K streaming.
  • Small Cell Network with MOCN, connecting a single eNodeB to multiple core networks.
  • Additionally, Sercomm’s entire portfolio of IoT sensors now supports the Matter Protocol for enhanced reliability and security.

VANTIVA Demonstrates Latest CPE Solutions for an Immersive Connected Home Experience at CES 2023

Retrieved on: 
Wednesday, January 4, 2023

LAS VEGAS, Jan. 4, 2023  /PRNewswire-PRWeb/ -- VANTIVA (formerly known as Technicolor) returns to CES to demonstrate the latest innovations in connected home technologies for broadband access, in-home wireless connectivity and enhanced video entertainment experiences.

Key Points: 
  • To this end, VANTIVA experts and executives will be on hand during the conference to showcase connected home technologies and applications embedded in the latest broadband and video CPEs.
  • Applications and products that will be demonstrated during CES include:
    Carrier Grade Wi-Fi 7 Gateway — VANTIVA unveiled the first fully operational gateway embedded with Wi-Fi 7 in the fall of 2022.
  • VANTIVA is demonstrating outdoor and indoor solutions that support 5G FWA connectivity to -- and throughout -- the home.
  • TV Analytics Solutions – VANTIVA and HERO Partner RealVNC will demonstrate next-generation analytics solutions and remote support capabilities for connected home subscribers.

New cloud platform 'STB CLOUD' disrupts AI Drug discovery worldwide

Retrieved on: 
Sunday, December 18, 2022

Powered by Syntekabio’s own MAHA supercomputing, the AI-based one-stop cloud service system STB CLOUD ensures the efficient discovery of small molecule drug candidates

Key Points: 
  • Powered by Syntekabio’s own MAHA supercomputing, the AI-based one-stop cloud service system STB CLOUD ensures the efficient discovery of small molecule drug candidates
    Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, has launched STB CLOUD worldwide.
  • Running on Syntekabio’s own supercomputing infrastructure, the new AI drug discovery cloud platform is driven by genomic big data and the latest AI technology.
  • By integrating DeepMatcher®, an AI-driven small molecule drug discovery platform, this new service has automated AI computing function within its own supercomputing hardware environment and database into the cloud system.
  • Improving standardization, simplification and automation of the existing computer-aided drug discovery (CADD) process optimizes the drug discovery and development process far better in terms of time, cost, accuracy and resources.

Global Cloud TV Market Report 2022: Demand for Improved On-Demand or Interactive Viewing User Experiences Boosts Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 9, 2022

The Global Cloud TV Market size is expected to reach $4.9 billion by 2028, rising at a market growth of 20.3% CAGR during the forecast period.

Key Points: 
  • The Global Cloud TV Market size is expected to reach $4.9 billion by 2028, rising at a market growth of 20.3% CAGR during the forecast period.
  • In 2006, ICTV and Switched Media, a company that creates solutions for the customization of video streams, merged to become ActiveVideo.
  • The lack of fast network infrastructure is one of the key obstacles to the widespread adoption of cloud TV.
  • For cloud TV providers, this problem has made it very difficult for them to reach out to remote areas.

Global Cloud TV Market to Reach $4.9 Billion by 2028 at a 20.3% CAGR

Retrieved on: 
Thursday, December 15, 2022

The Global Cloud TV Market size is expected to reach $4.9 billion by 2028, rising at a market growth of 20.3% CAGR during the forecast period.

Key Points: 
  • The Global Cloud TV Market size is expected to reach $4.9 billion by 2028, rising at a market growth of 20.3% CAGR during the forecast period.
  • To improve the cloud TV experience, many telecom providers are making investments in the development of 5G technologies.
  • The lack of fast network infrastructure is one of the key obstacles to the widespread adoption of cloud TV.
  • For cloud TV providers, this problem has made it very difficult for them to reach out to remote areas.

Audra Taylor joins executive team for Blood Operations at South Texas Blood & Tissue

Retrieved on: 
Tuesday, November 29, 2022

San Antonio, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- BioBridge Global and South Texas Blood & Tissue announced today that Audra Taylor, SBB, is joining the organization as Executive Director for Blood Operations.

Key Points: 
  • San Antonio, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- BioBridge Global and South Texas Blood & Tissue announced today that Audra Taylor, SBB, is joining the organization as Executive Director for Blood Operations.
  • She will report directly to Adrienne B. Mendoza, Chief Operating Officer, South Texas Blood & Tissue.
  • About South Texas Blood & Tissue: South Texas Blood & Tissue (STB&T) is a nonprofit community blood center that provides blood, plasma, platelets and other blood components to 100 hospitals in 48 South Texas counties.
  • STB&T has nine donor centers in South Texas and conducts hundreds of mobile blood drives each year.

FMCS Congratulates Parties in Resolving Gulf Coast Rail Dispute

Retrieved on: 
Friday, November 25, 2022

The parties began mediation with FMCS in June after the dispute was brought before the Surface Transportation Board (STB) in 2021.

Key Points: 
  • The parties began mediation with FMCS in June after the dispute was brought before the Surface Transportation Board (STB) in 2021.
  • The agreement brings the Gulf Coast one step closer to the restoration and expansion of passenger rail service between New Orleans and Mobile almost two decades after Hurricane Katrina caused a major disruption to the region's rail infrastructure.
  • "FMCS extends our congratulations to each of the parties and their leadership for their steadfast determination in coming to an agreement," FMCS Acting Director Greg Goldstein said.
  • The U.S. Federal Mediation & Conciliation Service (FMCS) is the nation's premier public agency for dispute resolution and conflict management.